{"DataElement":{"publicId":"5777362","version":"2","preferredName":"Crizotinib Agent Unplanned Change of Dose Made Dose Reduced Dose Modification Or Treatment on Hold Administered Descriptive Text","preferredDefinition":"A textual description of the Crizotinib unplanned change of dose made, reduced dose, modified dose or treatment on hold.","longName":"CZ_Unpln_Ds_Rdc_Tx_Mod_Txt","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"5777358","version":"2","preferredName":"Crizotinib Agent Unplanned Change of Dose Made Dose Reduced Dose Modification Or Treatment on Hold Administered","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.:An indication that the change in the agent dose regimen was not in the original documented treatment plan._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount._Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A treatment is suspended._The act of having given something (e.g., a medication or test).","longName":"5731690v1.0:8002377v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"5731690","version":"1","preferredName":"Crizotinib Agent","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","longName":"C74061:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C213504-F0E4-65FC-E053-F662850A793C","latestVersionIndicator":"Yes","beginDate":"2017-04-01","endDate":null,"createdBy":"CHANGP","dateCreated":"2017-04-01","modifiedBy":"ONEDATA","dateModified":"2017-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"11148633","version":"1","preferredName":"Unplanned Change of Dose Made Dose Reduced Dose Modification Or Treatment on Hold Administered","preferredDefinition":"An indication that the change in the agent dose regimen was not in the original documented treatment plan._An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount._Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._A treatment is suspended._The act of having given something (e.g., a medication or test).","longName":"11148633v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unplanned Change of Dose Made","conceptCode":"C70893","definition":"An indication that the change in the agent dose regimen was not in the original documented treatment plan.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"5"},{"longName":"Dose Reduced","conceptCode":"C49505","definition":"An indication that a medication schedule was modified by subtraction, either by changing the frequency, strength or amount.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Dose Modification","conceptCode":"C54346","definition":"Change, alteration, or adjustment of a dose specified in a treatment plan or/and administered to a patient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Treatment on Hold","conceptCode":"C106470","definition":"A treatment is suspended.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7023752-33B1-305F-E053-731AD00AC320","latestVersionIndicator":"Yes","beginDate":"2022-08-24","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-08-24","modifiedBy":"KUMMEROA","dateModified":"2022-08-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D53FE2D8-C596-0AE7-E053-4EBD850A8250","latestVersionIndicator":"Yes","beginDate":"2022-01-10","endDate":"2022-03-04","createdBy":"LAMEMIL","dateCreated":"2022-01-10","modifiedBy":"KUMMEROA","dateModified":"2022-08-24","changeDescription":"2022-03-04 retired orphaned DECs per context owner bsm.; Workflow and Registration Status Changed per Brenda Duggan; 05.16.18 Property updated EL 1/10/2022","administrativeNotes":"2022.8.24 Released. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2181231","version":"1","preferredName":"Descriptive Text","preferredDefinition":"The text that provides a description of a topic.","longName":"DESCR_TXT","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"ALPHANUMERIC","minLength":"1","maxLength":"200","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234203","version":"1","preferredName":"Text","preferredDefinition":"Text; the words of something written.","longName":"C25704","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Text","conceptCode":"C25704","definition":"The words of something written.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F89B-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D3B72801-8C4C-3772-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-19","endDate":null,"createdBy":"CURTIST","dateCreated":"2004-02-19","modifiedBy":"GDEEN","dateModified":"2022-05-31","changeDescription":"3/22/22 jk added \"Qualified\" RS as part of MCL quarterly content review.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"PQT","type":"Preferred Question Text","description":"Provide details of the Crizotinib unplanned change of dose made, reduced dose, modified dose or treatment on hold:","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Provide details of unplanned Crizotinib dose reduction or treatment held during this reporting period:","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"D695C35C-F464-76B3-E053-4EBD850AD5C3","latestVersionIndicator":"Yes","beginDate":"2022-01-27","endDate":null,"createdBy":"FEIBUSHL","dateCreated":"2022-01-27","modifiedBy":"KUMMEROA","dateModified":"2022-08-24","changeDescription":"Workflow and Registration Status Changed per Brenda Duggan; 05.16.18 Updated DEC EL 1/10/2022 Revised definition and Preferred Question Text LF 1/27/2022","administrativeNotes":"2022.8.24 Updated with DEC v2 and released CDE that LF created. ak","unresolvedIssues":null,"deletedIndicator":"No"}}